KOSDAQBiotech & Pharma226400

Osteonic

₩4,180▲ 2.45%2026-10-02 close

Market Cap

₩86.1B

Turnover

₩200M

Volume

60,000 shares

Shares out.

20.7M

PER

7.7×

PBR

1.1×

EPS

₩508

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Zimmer Partnership Drives Growth, Margin Stability Is the Test

Osteonic has posted four straight years of revenue growth on expanding Sports Medicine exports to Zimmer Biomet, though recent quarterly operating margins have settled below the 2025 Q2 level.

1
Revenue grew from KRW 19.8 billion in 2022 to KRW 45.4 billion in 2025, with operating margin improving from 12.7% to 19.5%.
2
US Sports Medicine exports to Zimmer Biomet rose 154.7% in H1 2026, leading overall growth.
3
The product portfolio continues to expand with US FDA approval for spine implants and domestic approval for the Suturepasser surgical tool.
4
Recent quarterly operating margins have stabilized in the high-teens, while net income shows notable quarter-to-quarter volatility from non-operating items.
5
US FDA approval for the Suturepasser is targeted by year-end 2026, and its outcome is a key point to watch for further global supply expansion.

Business structure

Osteonic develops and manufactures orthopedic implants using metal materials (stainless steel, titanium) and biomaterials (PEEK, biodegradable composites).

Its product lines span four categories: craniomaxillofacial (CMF), Trauma & Extremities, Sports Medicine, and Spine, with the Spine implant—domestically approved in 2023—also receiving US FDA approval in H1 2026, giving all four lines a global supply framework.

In 2020, the company signed a global exclusive supply agreement for Sports Medicine products with Zimmer Biomet, the world's second-largest orthopedic device maker, and US market ODM supply ramped up from May 2025.

In H1 2026, CMF revenue reached KRW 6.1 billion and Trauma solutions revenue reached KRW 8.1 billion, while Spine implant revenue rose 58.4% year-on-year to KRW 900 million. Beyond Zimmer Biomet, Osteonic supplies CMF products in Europe through distribution channels including B.

Braun, and reportedly has sales networks across 58 countries.

On the new product front, the disposable surgical tool 'Suturepasser,' developed at Zimmer Biomet's request, received domestic approval from South Korea's Ministry of Food and Drug Safety in July 2026 and is pursuing US FDA approval to enable global supply through Zimmer's distribution network.

A new Sports Medicine product for meniscus cartilage repair has completed US patent registration and is undergoing the FDA approval process.

Competitively, the company operates alongside numerous small and mid-sized orthopedic implant makers domestically and abroad, but its business model relies heavily on ODM supply through a major global partner rather than direct branded sales.

Earnings trend

Quarterly revenue · Operating profit

₩11B₩2.7B25Q2₩11.9B₩2.2B25Q3₩13B₩2.4B25Q4₩12.9B₩2.3B26Q1₩13.2B₩2.4B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩19.8B₩2.5B2022₩27.8B₩4.8B2023₩34.2B₩6.9B2024₩45.4B₩8.9B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩11B	₩2.7B	25.0%
2025Q3	₩11.9B	₩2.2B	18.7%
2025Q4	₩13B	₩2.4B	18.4%
2026Q1	₩12.9B	₩2.3B	18.1%
2026Q2	₩13.2B	₩2.4B	18.4%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩19.8B	₩2.5B	₩800M	12.7%	2.3%	68.6%
2023	₩27.8B	₩4.8B	₩3.7B	17.4%	7.1%	38.3%
2024	₩34.2B	₩6.9B	₩5.6B	20.1%	9.5%	51.6%
2025	₩45.4B	₩8.9B	₩7.5B	19.5%	11.1%	48.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23

Earnings analysis

Osteonic's consolidated revenue rose for four consecutive years, from KRW 19.8 billion in 2022 to KRW 27.8 billion in 2023, KRW 34.2 billion in 2024, and KRW 45.4 billion in 2025. Operating profit expanded from KRW 2.5 billion to KRW 8.9 billion over the same period, with operating margin improving from 12.7% to 19.5%.

Net income attributable to owners also grew sharply, from roughly KRW 800 million in 2022 to KRW 7.5 billion in 2025.

On a quarterly basis, after posting revenue of KRW 11.0 billion and operating profit of KRW 2.7 billion (an operating margin of roughly 25%) in Q2 2025, revenue climbed steadily to KRW 11.9 billion in Q3 2025, KRW 13.0 billion in Q4 2025, KRW 12.9 billion in Q1 2026, and KRW 13.2 billion in Q2 2026, while operating margin stabilized in the mid-to-high teens.

Net income showed considerable quarter-to-quarter volatility: in Q4 2025, net income of KRW 3.7 billion exceeded operating profit of KRW 2.4 billion, whereas in Q2 2026 net income of KRW 1.8 billion fell below operating profit of KRW 2.4 billion, indicating that non-operating items materially affect quarterly results.

Cumulative H1 2026 results showed revenue of KRW 26.1 billion, operating profit of KRW 4.8 billion, and net income of KRW 4.5 billion, driven by a 154.7% increase in US Sports Medicine exports to Zimmer Biomet.

Owners' net income summed over the most recent four quarters (Q3 2025 through Q2 2026) reached approximately KRW 10.2 billion, marking a step-up in the annualized earnings base.

Company officials stated they achieved meaningful results even in the relatively slower first half, and expect a record annual performance given the tendency for larger revenue and operating profit gains in the second half.

Industry analysis

The orthopedic implant market continues to grow steadily, driven by rising degenerative disease incidence from an aging population and increasing ligament and cartilage injury demand tied to sports activity.

Focusing on spine implants alone, GrandView Research put the global market at USD 13.9 billion (roughly KRW 20 trillion) in 2024, with the US forming the largest single market at USD 6.4 billion.

In Sports Medicine, biomaterial-based products used for ligament reconstruction account for the bulk of the market, and Osteonic differentiates itself by leveraging its proprietary biodegradable composite material within an exclusive partnership with Zimmer Biomet, the world's second-largest orthopedic device company.

However, Osteonic remains small in revenue scale relative to large domestic and international orthopedic implant makers, and its growing reliance on a single major customer, Zimmer Biomet, is a notable factor in its industry positioning.

The company is reportedly discussing ODM supply agreements with multiple global device makers in the Trauma segment, and is pursuing new sales channels for CMF beyond its existing B. Braun distribution relationship, reflecting ongoing efforts at customer diversification.

In the broader orthopedic surgery market, adoption of advanced technologies such as robotic surgery and 3D-printed implants is expanding, with the spread of minimally invasive procedures cited as a structural factor supporting demand for implants and related surgical instruments.

Outlook

The company is pursuing US FDA approval for the Suturepasser with a year-end 2026 target, and expects full-scale global supply through Zimmer Biomet's distribution network upon approval.

A new Sports Medicine product for meniscus cartilage repair has also completed US patent registration and is undergoing FDA review, which could further expand the Sports Medicine portfolio depending on approval timing.

In an August 3, 2026 report, SK Securities projected structural sales growth as Zimmer Biomet-bound supply expands from anchors alone to surgical tools and biomaterials, and noted that a new collagen patch product is also under development.

In the same report, SK Securities forecast FY2026 revenue of KRW 57.5 billion and operating profit of KRW 12.1 billion, issuing a 'Buy' rating and a target price of KRW 10,300, consistent with company commentary that solid first-half results support expectations for a stronger second-half seasonal effect.

In the Trauma segment, ODM supply agreement discussions with multiple global device makers are reportedly underway, which could diversify the customer base beyond Zimmer Biomet if finalized.

For spine implants, the company has outlined plans to expand export regions to Latin America, Southeast Asia, and the Middle East following US FDA approval.

However, the timing and scale of revenue contribution from these new product lines will depend on the completion of country-specific regulatory approvals, making it necessary to track actual disclosed quarterly and annual results to gauge progress.

Valuation

PER

7.7×

PBR

1.1×

ROE

15.2%

EPS

₩508

BPS

₩3,582

Dividend per share

₩0

Osteonic has shown a trend of expanding profitability over recent years, moving from losses to a growing earnings base alongside steady revenue and operating profit gains.

As the earnings base has grown, the price-to-earnings level has settled in a lower range than in prior periods, while the price-to-book ratio trades at a modest premium to net asset value. The company currently pays no dividend, so shareholder returns depend on continued earnings growth and any future policy changes.

Within the KOSDAQ small-cap bio/medical device sector, the stock is generally categorized as one with clear earnings improvement, but given its small market capitalization and limited liquidity, valuation metrics can also swing more sharply than larger peers.

Investors should track upcoming quarterly disclosures and new product certification progress to assess directly whether the earnings improvement continues.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23

Bull factors

Expanding Zimmer Biomet Partnership

Building on the 2020 global exclusive Sports Medicine supply agreement, US exports to Zimmer Biomet entered a second-year reorder cycle, surging 154.7% in H1 2026.

New product development for items like the Suturepasser and a meniscus repair product, initiated at Zimmer Biomet's request, points to a broadening revenue base as the supplied product range expands.

The shift from anchor-centric supply to surgical tools and biomaterials is viewed as a qualitative growth factor beyond simple volume gains.

Broad-Based Product Portfolio Expansion

Following FDA approvals for CMF, Trauma, and Sports Medicine products, the company also secured US approval for spine implants, completing coverage across the major bone-related implant categories.

While Spine implant revenue was relatively small through 2025, it grew 58.4% year-on-year in H1 2026, emerging as a new growth driver. This product diversification can help spread demand risk across categories rather than concentrating it in a single line.

Multi-Year Revenue and Profit Growth Trend

Revenue increased every year from 2022 through 2025, more than doubling over four years, while operating margin also improved from 12.7% to 19.5%. Net income attributable to owners expanded significantly over the same period, reflecting a steadily strengthening earnings base. This growth trajectory is notable in that it is anchored to a clear driver: expanding exports to Zimmer Biomet.

Bear factors

Growing Reliance on a Single Customer

As the core growth driver is concentrated in Sports Medicine exports to Zimmer Biomet, any change in contract terms or renewal issues with that customer could have a significant impact on results. New ODM agreement discussions in the Trauma segment have not yet translated into confirmed outcomes. Customer diversification may take time before it becomes visible in actual revenue.

Operating Margin Plateau

After reaching roughly 25% in Q2 2025, operating margin has stayed in the mid-to-high teens for four consecutive quarters, suggesting margin improvement has lagged behind revenue growth.

SK Securities has noted that new product development costs and one-time expenses related to European CE MDR certification could weigh on margins. If such certification-related costs persist, near-term margin improvement could remain constrained.

Low Liquidity Typical of a Small-Cap Stock

Given its small market capitalization and relatively limited trading volume, the stock can exhibit greater price volatility as a small-cap issue.

Since net income swings considerably from quarter to quarter due to non-operating factors, caution is warranted in judging business direction from short-term earnings figures alone. Low-liquidity stocks can also see relatively larger price moves in response to shifts in supply and demand.

Risk factors

Customer Concentration Risk

A substantial portion of revenue growth depends on ODM supply to Zimmer Biomet, so any change in contract terms or order volume could directly affect results. While customer diversification is being pursued in the Trauma and CMF segments, this remains at an early stage, and reducing dependence may take time.

Regulatory and Certification Delay Risk

Both the Suturepasser and the new meniscus repair product are undergoing US FDA approval processes, and any delay in approval timing could correspondingly push back the associated revenue contribution.

Tightening medical device certification requirements in various jurisdictions, such as Europe's CE MDR, could also add cost and schedule burdens to certification.

Currency and Trade Environment Risk

Given the export-heavy business structure, fluctuations in the won-dollar exchange rate can affect profitability. The company has stated that US tariff impact is currently limited, but the possibility that future changes in trade policy could affect export profitability cannot be ruled out.

What to watch next

Mid-November 2026
The statutory filing deadline for the Q3 2026 report (November 16) — a point to check Q3 revenue, operating profit, net income, and Sports Medicine export trends.
Late 2026
The point at which US FDA approval status for the Suturepasser should become clear; if approved, it is worth checking whether global supply through Zimmer Biomet's network begins.
Q4 2026
A point to check progress on US FDA approval for the new meniscus cartilage repair product.
Q4 2026 to early 2027
It is worth checking whether the ODM supply agreements under discussion with multiple global companies in the Trauma segment are finalized.
Around March 2027
The expected filing time for the FY2026 annual report, allowing a check on whether full-year revenue and operating profit matched brokerage forecasts.

Overall view

Osteonic has grown revenue and operating profit for four consecutive years since 2022 on the back of its exclusive partnership with Zimmer Biomet, while continuously broadening its product portfolio through Spine and Sports Medicine certifications.

US exports to Zimmer Biomet surged 154.7% in H1 2026, driving overall growth, though operating margin has come down from the elevated Q2 2025 level and stabilized in the high-teens over the past four quarters.

Net income has shown considerable quarter-to-quarter volatility from non-operating factors, warranting separate attention from the operating profit trend.

Several events remain to be confirmed, including US FDA approval for the Suturepasser and meniscus products and new ODM agreements in the Trauma segment, and their realization and timing will be key variables for future results.

At the same time, growing reliance on a single customer, Zimmer Biomet, and the low liquidity typical of a small-cap stock are factors that warrant consideration.

Ahead of any investment decision, tracking upcoming quarterly disclosures and new product certification progress is a reasonable approach to directly verify the sustainability of this growth.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-30 · Data as of 2026-09-29

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.